A Phase II, Safety and Efficacy Study of Fixed Dose Radioimmunotherapy (Zevalin, Yttrium-90 Ibritumomab Tiuxetan) for Patients With Incomplete Response to Chemotherapy Prior to Autologous Stem Cell Transplant for Multiple Myeloma

Trial Profile

A Phase II, Safety and Efficacy Study of Fixed Dose Radioimmunotherapy (Zevalin, Yttrium-90 Ibritumomab Tiuxetan) for Patients With Incomplete Response to Chemotherapy Prior to Autologous Stem Cell Transplant for Multiple Myeloma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Melphalan; Rituximab
  • Indications Multiple myeloma
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 10 Feb 2017 Status changed from completed to discontinued.
    • 20 Dec 2016 Status changed from discontinued to completed.
    • 07 Sep 2016 Status changed from completed to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top